ClinicalTrials.Veeva

Menu

Evaluate the Auxiliary Diagnostic Value of Circulating Tumor Cells in Benign and Malignant Lung Nodules

G

GenoSaber

Status

Unknown

Conditions

Solitary Pulmonary Nodule

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT02653859
CTC2015-02

Details and patient eligibility

About

By testing the CTC number of new solitary pulmonary nodule patient, evaluating the correlation of CTC number and benign and malignant lung nodules auxiliary diagnosis, the correlation of CTC number and the size of lung nodules of the malignant patients, the correlation between the CTC number and subtypes of malignant lung nodules patients.The CTC and tumor markers will be detected before the patient received treatment. Tumor markers include Pro-GRP, NSE, CEA, CYFRA211, SCC.

Enrollment

50 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • New Solitary Pulmonary Nodule patients
  • first visit patient
  • Heart, liver and kidney function is normal.
  • 18-80 years old.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

  • Blood collection time is not in the scheduled time.
  • The plasma sample hemolysis or condensation.
  • Whole blood samples less than 3 ml.
  • poor compliance

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems